Loading
Life sciences · Journal article
Biomaterials · August 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Oral strategies for obesity and its associated metabolic dysfunction rarely coordinate nutrient digestion, microbial ecology, barrier integrity and low-grade inflammation within the gastrointestinal lumen. Here we report an interface-engineering strategy that converts flavonoid monomers into oligomerized flavonoid-derived polyphenolic nanointerfaces for local gastrointestinal regulation. Five representative flavonoids were oligomerized through an acetaldehyde-mediated reaction and assembled into carrier-free nanoparticles with clustered surface phenolic motifs. Among them, oligomeric EGCG nanoparticles (O-EGCG NPs) showed the strongest interfacial activity, outperforming monomeric EGCG and non-assembled oligomers. Mechanistic analyses showed that O-EGCG NPs non-competitively modulated α-glucosidase, α-amylase, pancreatic lipase and pancreatic cholesterol esterase through enzyme binding and conformational remodeling. After oral administration, the nanoparticles maintained gastrointestinal colloidal stability, prolonged intestinal retention and reduced postprandial carbohydrate and lipid flux in substrate and mixed-meal tolerance tests. Repeated administration in high-fat diet-fed mice attenuated body-weight gain, hepatic lipid accumulation, dyslipidaemia and insulin resistance, accompanied by changes in intestinal barrier status, inflammatory cytokines and gut microbiota composition. These findings establish oligomerized flavonoid nanoparticles as locally acting luminal nanomaterials for regulating nutrient processing and microbiota-associated metabolic inflammation.